Bio-Rad Laboratories, Inc. $BIO Shares Bought by Assetmark Inc.

Assetmark Inc. boosted its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 36.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,808 shares of the medical research company’s stock after buying an additional 7,633 shares during the period. Assetmark Inc. owned approximately 0.11% of Bio-Rad Laboratories worth $8,077,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the company. Farther Finance Advisors LLC boosted its holdings in Bio-Rad Laboratories by 52.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 36 shares in the last quarter. UMB Bank n.a. boosted its stake in shares of Bio-Rad Laboratories by 24.0% in the third quarter. UMB Bank n.a. now owns 207 shares of the medical research company’s stock valued at $58,000 after buying an additional 40 shares in the last quarter. Frank Rimerman Advisors LLC boosted its stake in shares of Bio-Rad Laboratories by 3.0% in the second quarter. Frank Rimerman Advisors LLC now owns 1,806 shares of the medical research company’s stock valued at $436,000 after buying an additional 53 shares in the last quarter. Oppenheimer Asset Management Inc. grew its holdings in Bio-Rad Laboratories by 1.9% during the second quarter. Oppenheimer Asset Management Inc. now owns 2,871 shares of the medical research company’s stock worth $693,000 after acquiring an additional 54 shares during the period. Finally, M&T Bank Corp raised its position in Bio-Rad Laboratories by 3.7% in the second quarter. M&T Bank Corp now owns 1,855 shares of the medical research company’s stock worth $447,000 after acquiring an additional 66 shares in the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Down 12.2%

Shares of BIO stock opened at $256.87 on Tuesday. The firm has a 50-day moving average price of $304.44 and a 200 day moving average price of $301.63. Bio-Rad Laboratories, Inc. has a twelve month low of $211.43 and a twelve month high of $343.12. The company has a market capitalization of $6.93 billion, a price-to-earnings ratio of 9.20 and a beta of 1.18. The company has a current ratio of 5.62, a quick ratio of 4.19 and a debt-to-equity ratio of 0.16.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Thursday, February 12th. The medical research company reported $2.51 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.06). The firm had revenue of $693.20 million for the quarter, compared to analyst estimates of $694.64 million. Bio-Rad Laboratories had a return on equity of 3.86% and a net margin of 29.42%.The firm’s revenue was up 3.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.90 EPS. Research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on BIO. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research note on Monday, December 29th. Wells Fargo & Company upped their target price on shares of Bio-Rad Laboratories from $265.00 to $340.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Citigroup lifted their price target on shares of Bio-Rad Laboratories from $350.00 to $375.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Finally, Wall Street Zen cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Saturday. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $358.50.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.